An Investigator-initiated, Randomized, Double-blind, Placebo Controlled Study of Apremilast to Demonstrate Efficacy in Subjects With Nummular Eczema
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Apremilast (Primary)
- Indications Eczema
- Focus Therapeutic Use
- Acronyms APREMINUM
- 17 Sep 2018 Planned End Date changed from 1 Jul 2019 to 1 Mar 2020.
- 17 Sep 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2019.
- 16 Aug 2017 Status changed from not yet recruiting to recruiting.